Gilead kicks off clinical trial of inhaled remdesivir for less-severe COVID-19 Premier survey: Nearly all hospitals stockpiling drugs to prepare for second COVID-19 surge Want to defeat COVID-19? Deliver a 70% effective vaccine—and get 70% of people to take it, FDA official says What doctors should know as debate heats up around schools reopening in fall Biden-Sanders task force health platform pushes for public option, a free COVID-19 vaccine NIAID creates new COVID-19 drug and vaccine trial network through Trump's Warp Speed program Oxford researchers develop portable COVID-19 test costing less than $25 Biopharma roundup: FDA official floats 70% vaccine efficacy bar; AZ, Pfizer, J&J to testify on vaccine progress Healthcare roundup: Azar voices support for telehealth expansion; Geisinger CEO on second surge Moderna inks fill-finish pact with Spain's Rovi for 'hundreds of millions' of COVID-19 shot doses GSK's Shingrix supply recovers thanks to drop in vaccinations, uninterrupted production Featured Story | By Angus Liu Gilead has started a clinical trial of inhaled remdesivir in 60 U.S. healthy volunteers. The hope is that the inhaled formulation—as compared with the drug’s currently available intravenous form—could reach the outpatient setting, where patients have less severe disease, and that early treatment could help them avoid hospitalization. read more |
| |
|---|
|
| | [Webinar] Zero Deviation Mindset: Achieving Agility in Cell Therapy Supply Chains Tuesday, July 21 | 10am ET / 7am PT Join Thermo Fisher Scientific and Pluristem Therapeutics as we discuss lessons learned in developing the just-in-time supply chain for their phase III hip fracture study, and how these lessons are being used in their current efforts to treat severe COVID-19 cases complicated by Acute Respiratory Distress Syndrome (ARDS) in the United States. Register Now. |
Top Stories By Robert King Premier members are stockpiling drugs needed to treat COVID-19 patients as concerns about a second surge of cases grows, a new survey found. read more By Eric Sagonowsky One of public health's greatest accomplishments was eradicating smallpox back in 1979. To eradicate SARS-CoV-2, the virus that causes COVID-19 illness, we'll need a vaccine that's 70% effective—and 70% of the population will need to receive it, an FDA vaccine official said Wednesday. read more By Tina Reed As the U.S. suffers surges in COVID-19 cases in states that have begun reopening their economies, it's fanned the flames of a growing debate: How should schools proceed with instruction in the fall? read more By Paige Minemyer Presumptive Democratic presidential nominee Joe Biden's campaign released his healthcare platform shaped by a series of progressive task forces. read more By Ben Adams The National Institute of Allergy and Infectious Diseases is launching a new clinical trial network to seek out and add thousands of volunteers to major clinical tests for vaccines and monoclonal antibodies against the pandemic. read more By Conor Hale The University of Oxford and its research center in China are launching a new company to develop a rapid COVID-19 test that could cost no more than £20, or about $25 U.S. read more By Eric Sagonowsky,Angus Liu,Kyle Blankenship,Conor Hale,Fraiser Kansteiner The FDA's Peter Marks thinks it will take a COVID-19 shot with 70% efficacy to eradicate the virus. The Center for Health Security at Johns Hopkins issued a report on the public's role in vaccination. Plus, J&J, AZ, Moderna and more will report their vaccine progress before a House subcommittee this month. read more By Healthcare Staff Follow along with the latest COVID-19 news straight from the Fierce Healthcare team. read more By Kyle Blankenship Moderna is on a steady march to market with its mRNA-based COVID-19 vaccine, and it's snapping up manufacturing capacity along the way. After inking a fill-finish deal with major CDMO Catalent last month, Moderna has now put its name to a second pact, this time with Madrid-based Rovi. read more By Eric Sagonowsky After COVID-19 lockdowns caused a steep decline in healthcare visits, Shingrix vaccinations slowed. The company has been producing its vaccine throughout the pandemic, so it now has available supply to meet a bounce-back in demand, a spokesman said. read more |
